J Vet Sci.  2019 Mar;20(2):e2. 10.4142/jvs.2019.20.e2.

Development of Actinobacillus pleuropneumoniae ApxI, ApxII, and ApxIII-specific ELISA methods for evaluation of vaccine efficiency

  • 1Department of Microbiology, Research Institute of Life Sciences, Gyeongsang National University School of Medicine, Jinju 52727, Korea.
  • 2Department of Infectious Diseases, College of Veterinary Medicine, Seoul National University, Seoul 08826, Korea. yoohs@snu.ac.kr
  • 3Choong Ang Vaccine Laboratories Co., Ltd., Daejeon 34055, Korea.


Among various vaccines against Actinobacillus pleuropneumoniae, subunit vaccines using recombinant proteins of ApxI, ApxII, and ApxIII as vaccine antigens have shown good efficacy in terms of safety and protection. Therefore, subunit vaccines are being applied worldwide and the development of new subunit vaccines is actively being conducted. To evaluate the efficacy of the subunit vaccines, it is important to measure immune responses to each Apx toxin separately. However, the cross-reactivity of antibodies makes it difficult to measure specific immune reactivity to each toxin. In the present study, specific antigen regions among the toxins were identified and cloned to solve this problem. The antigenicity of each recombinant protein was demonstrated by Western blot. Using the recombinant proteins, we developed enzyme-linked immunosorbent assay (ELISA) methods that can detect specific immune responses to each Apx toxin in laboratory guinea pigs. We suggest that the ELISA method developed in this study can be an important tool in the evaluation of vaccine efficiency and vaccine development.


Actinobacillus pleuropneumoniae; Apx toxins; vaccines, subunit; ELISA
Full Text Links
  • JVS
export Copy
  • Twitter
  • Facebook
Similar articles
Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr